Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matthew K. Fust Insider Profile
4 Followers
Matthew K. Fust, Director at Ultragenyx Pharmaceutical, holds 259.00K shares in Atara Biotherapeutics (Ticker: ATRA), holds 18.54K shares in Crinetics Pharmaceuticals (Ticker: CRNX), holds 14.86K shares in Ultragenyx Pharmaceutical (Ticker: RARE).
Matthew K. Fust Ultragenyx Pharmaceutical (RARE)Director
Ultragenyx Pharmaceutical (RARE)
Director
Ranked #8,718 out of 98,624 Corporate Insiders
Profitable Transactions
8 out of 14 Profitable Transactions
Average Return
+15.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Matthew K. Fust holds in companies
Most Profitable Insider Trade
Stock:
Dermira
(~DERM)
(~DERM)
Rating:Informative Buy
Date:Nov 26, 2014 - Nov 26, 2015
Return:+69.50%
The most profitable trade made by Matthew K. Fust
Matthew K. Fust's Trading History
Ultragenyx Pharmaceutical
Mar 11, 2024
Director
Informative Sell
620.44K
$657.41K
Crinetics Pharmaceuticals
Mar 22, 2024
Director
Informative Buy
1.25M
$780.74K
Dermira
Dec 26, 2019
―
Uninformative Sell
45.00K
$94.71K
MacroGenics
Feb 08, 2019
Director
Uninformative Sell
203.43K
$7.28K
Atara Biotherapeutics
Apr 02, 2024
Director
Uninformative Buy
―
$178.71K
Jazz Pharmaceuticals
―
EVP & CFO
―
$6.45M
Onyx Pharma
―
―
―
―
List of latest transactions for each holding click on a transaction to see Matthew K. Fust's performance on stock
You May Also Like
Matthew K. Fust insider profile FAQ
What is the percentage of profitable transactions made by Matthew K. Fust?
The percentage of profitable transactions made by Matthew K. Fust is 57%.
What is the average return per transaction made by Matthew K. Fust?
The average return per transaction made by Matthew K. Fust is 15.30%.
What stocks does Matthew K. Fust hold?
Matthew K. Fust holds: RARE, CRNX, ~DERM, MGNX, ATRA, JAZZ, ONXX stocks.
What was Matthew K. Fust’s latest transaction?
Matthew K. Fust latest transaction was an Uninformative Buy of ―.
What was Matthew K. Fust's most profitable transaction?
Matthew K. Fust’s most profitable transaction was an Informative Buy of ~DERM stock on November 26, 2014. The return on the trade was 69.50%.
What is Matthew K. Fust's role in Ultragenyx Pharmaceutical?
Matthew K. Fust's role in Ultragenyx Pharmaceutical is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.